Here are the 10-Q quarterly reports from Tivic Health Systems, Inc. (TIVC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TIVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIVC filings page.
Valion Bio, Inc. reported a net loss of $6.2 million for the three months ended March 31, 2026, compared with $1.5 million a year earlier, driven by sharply higher research and development and selling, general and administrative expenses. Cash and cash equivalents were $7.2 million at March 31, 2026, after using $5.0 million in operating cash during the quarter, and accumulated deficit reached $59.0 million. The company’s financial statements state that these factors raise “substantial doubt” about its ability to continue as a going concern without additional financing. Valion expanded through the 2025 acquisition of Scorpius’ CDMO assets and entered long-term facility leases, recording operating lease right-of-use assets of $10.1 million. It also carries a senior secured convertible note with $16.3 million principal and a derivative liability. In March 2026, Valion received a Nasdaq notice that its share price fell below the $1.00 minimum bid requirement and has until September 15, 2026 to regain compliance.
Tivic Health Systems, Inc. (TIVC) reports financing and corporate activity for the quarter ended June 30, 2025. The company shows multiple financings: a registered offering that raised gross proceeds of approximately $4.0 million (net ~ $3.3 million) allocated between common stock ($1.4 million) and warrants ($1.9 million); a Tranched Financing structured to raise up to $8.4 million through sales of Series B Preferred Stock and warrants; and an Equity Line of Credit enabling sales of up to 25 million common shares over 24 months. Mast Hill purchased shares under the Purchase Agreement during Q2 2025 (87,558 shares for gross proceeds of $332 thousand, net $311 thousand).
Balance-sheet and cash items disclosed include money market funds of $1.0 million at June 30, 2025 (versus $1.8 million at December 31, 2024), deferred financing costs related to prior offerings, and $500 thousand Neutropenia Milestone Payment paid in company stock and capitalized as licensed technology. The company reports no impairments of long-lived assets for periods presented and describes multiple contractual obligations and milestone arrangements, including a $5.6 million Payoff Amount allocation between Statera and Avenue. The filing contains forward-looking statements and identifies risks and uncertainties affecting future results.